Pharmaceutical & Nutritional Products Supplier From China
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Established in 2017
Over 500 long term cooperation clients
More than 200 close-related suppliers
Anual sales exceeding 10,000,000 US dollars
Nutritional IngredientsDerives From The Nature To Maintain
Body Health And Balance With Purity
Development
Serum Pharma will continuously monitor the development of the cutting-edge markets, Currently, we have already cooperated with our partners on the customization of Pre-Mix, Co-Crystallization and Bio-Fermentation products service, and have launched corresponding support services, Details are as below;
Do you really think a low price alone qualifies you as a secondary supplier? In fact, 90% of API manufacturers haven't even fully considered this aspect.
On the competitive landscape of generic drug active pharmaceutical ingredients (APIs)https://www.jxserum.com/apis-intermediates/, the same scenario plays out every day:
You entered the market with confidence, armed with the promise of "better quality at lower prices," only to find that despite your best efforts, you could secure merely a symbolic 10–20% share. In contrast, the seemingly ordinary primary supplier held firmly over 70% of the orders, demonstrating unshakable dominance.
Many API providers are outraged, viewing their customers as irrational and overly conservative in their decision-making.
To customers, the decision to choose you isn't based on how good you are—it's simply about whether switching to you is truly worthwhile.
Today, we have thoroughly clarified this entire accounting process from beginning to end. Only by reading this article can you truly grasp the fundamental dynamics of the commercial competition in the generic drug market.
Why Tetanus Antitoxin is Essential for Livestock in Africa
Introduction: A Silent Threat to Africa’s Livestock Economy
Africa is home to one-third of the world’s livestock-. The continent’s livestock sector supports an estimated 350 million people and contributes 12% to Africa’s GDP and 42% to its agricultural GDP. In countries like Kenya, livestock accounts for 42% of agricultural GDP-; in some nations, it contributes up to 80% of national GDP-. The Africa Livestock Market was valued at approximately $75 billion in 2022 and is projected to reach $125 billion in the coming years.
Yet behind these impressive numbers lies a persistent and preventable threat: tetanus. While tetanus has become a rarity in developed countries due to routine vaccination-13, it remains a daily danger for millions of livestock and working animals across Africa. For veterinary biologics suppliers like your company — already equipped with UAE registration and a price-competitive Tetanus Antitoxin (TAT) product — this represents not just a humanitarian opportunity, but a significant market opening.
Plant-derived Squalene Market Analysis
WHITE PAPER: The Global Squalene Market
Sustainable Sourcing, Regulatory Landscapes, and Strategic Opportunities (2025-2034)
Publication Date: April 2026
Target Audience: Cosmetic Brand Owners, Pharmaceutical Procurement, Raw Material Distributors
Executive Summary
The global squalene market is undergoing a fundamental transformation. Driven by regulatory pressure in Europe, ESG (Environmental, Social, and Governance) commitments from major brands, and biotechnological innovation, the industry is rapidly shifting away from traditional animal sources toward plant-based and biosynthetic alternatives.https://www.jxserum.com/other-extracts/
This white paper provides a data-driven analysis of the market dynamics, regulatory frameworks (specifically the EU ban on shark-derived squalene in cosmetics), supply chain challenges, and the forecasted growth trajectory through 2034.
Key Findings:
-
Market Growth: The market is projected to grow from USD 185.03 million (2025) to USD 437.36 million by 2034, at a CAGR of 10.10% .
-
Regional Dominance: Europe holds 48% of the global market share, driven by stringent sustainability laws .
-
Segmentation: Cosmetics represent 70.51% of end-use, but Pharmaceuticals (vaccine adjuvants) are the fastest-growing segment.
-
Sourcing Shift: Plant-derived squalene is the fastest-growing source type, responding to the ban on animal-derived versions in key regions .
